Mar 08, 2023 / 07:10PM GMT
Ernie Rodriguez - TD Cowen - Biotech Analyst
So we'll get things started. Welcome everyone to our cell therapy corporate panel at the 43rd Annual Healthcare Conference. I'm Ernie Rodriguez from the biotech team at TD Cowen, and I'm joined by my colleagues; Boris Peaker, Yaron Werber, and [Jenna Hahn].
And we have the pleasure today to have a great panel of representatives in the cell therapy space. We have CEO Adrian Rawcliffe from Adaptimmune; President and CEO, Pascal Touchon from Atara Biotherapeutics; President and CEO Paul Hastings from Nkarta; and President and CEO David Southwell from TScan.
Questions and Answers:
Ernie Rodriguez - TD Cowen - Biotech AnalystSo thank you very much for joining us. We are going to start the conversation with a few thematic questions on the space overall, and then we'll do a round robin between the individual companies under specific programs.
So I guess asking the panel, over the past year, year or so, we have seen a number of regulatory delays, holds, on cell therapy programs. From these